Newsletter

OTCJ: Hot Penny Stock: Possible Swine Flu Therapy Brings Investors

Home Page : www.otcjournal.com
Email Questions or Comments To: editor@otcjournal.com

To OTC Journal Members: 

I am going to keep introducing new ideas in China companies- some smaller, some larger. I believe there will be a flood of capital pouring into this area. When capital starts to look for growth on a global basis, China is where they will find it.

Here's the challenge- how do you know what you're investing in? The communication barrier makes things difficult. There have been some companies that appear to have some level of fraudulent activity.

One way to achieve this goal is to form an alliance with a professional who has infrastructure within China, and has people on the ground monitoring and supervising. 

One of my alliances for China situations was interviewed this past Thursday on Bloomberg TV on the Asian pre market show. He specifically mentions both China Energy Recovery (CGYV), and NF Energy (NFES).

To view a replay of the video clip, all you have to do is CLICK HERE, and the player should simply blow open on your computer monitor. Turn on your speakers.
 

Hot Penny Stock: Possible Swine Flu Therapy Brings Investors Piling Into to Cel-Sci (AMEX: CVM)

The WHO (I'm not kidding- World Health Organization) has officially declared the Swine Flu as a world wide pandemic. This past week, the WHO raised the Swine Flu to "Phase 6", it's highest level for global risk.

The Phase 6 alert does not mean the severity is increasing- it means the spread is more global. The Phase 6 ranking opens the door to accelerated production and research on a number of possible therapies and vaccines.

One company getting major recognition for a possible therapy is AMEX listed Cel-Sci (CVM), a stock I have been following on and off for many years.

Last week, CVM announced its L.E.A.P.S (Ligand Epitope Antigen Presentation System) technology, could represent an immune based therapy for swine flu, and had shown promise.

At the Naval Medical Research Center in Silver Spring, MD, L.E.A.P.S has demonstrated an ability to enhance the body's natural protection against many different kinds of diseases. The Navy is focused on using the therapy to treat Malaria.

This past week, CVM announced it was developing an immune based treatment for the Swine Flu, and the stock went absolutely ballistic. 

The stock traded 32 million shares in one day last week, the highest volume in its more than 20 years of being a publicly traded company. It also surged from about $.25 to $.80 in one day. Pretty crazy.

Here's why I'm bringing this to your attention- the stock has now completed a perfect 61.8% retracement of that entire move, and could be poised to head up again. There is certainly significant interest from both investors and traders.

If this $.47 level gives way, it is likely to come back down and fill the gap that was created on the 32 million share day. This would take the stock down to the $.36 mark, at which point it would be highly likely to turn around and head back up.

The story on CVM goes far beyond a possible Swine Flu vaccine. CVM has been developing a cancer therapy for many years, and in world wide Phase II clinical trials it has delivered awesome results. Multikine- their flagship drug- is being readied for world wide Phase III clinical trials as a therapy for the virtually untreatable head and neck cancers.

In the process of preparing to enter a Phase III trial for Multikine, CVM has financed and built a small FDA approved lab where the compound can be synthesized. Look for CVM to become an outsourced solution for other drug developers to have smaller amounts of their compounds created for use in world wide clinical trials as well.

For those of you looking for a great trade on the Swine Flu world wide pandemic, CVM looks like it has caught the idea of investors. A good way to trade this stock would be to take a small position now. If you see a pullback to the $.36 level, load up with a tight stop.
 

  Comments in the BLOG  

Since I was in Europe for 2 weeks attending conferences with Swiss money managers on small to mid size China companies, I fell a bit behind on both BLOG postings and responses. I got caught up with two new postings yesterday- my latest new idea- NF Energy (NFES)- a hot China Stock has a posting offering some technical comments. I also posted a long overdue update on the recent pullback in China Energy Recovery (CGYV)- of late, not such a hot China stock, but coming back. Use the BLOG postings as an opportunity to ask any questions or post any well thought out comments, both to the positive or negative side. Click Here for NFES; Here for CGYV, or go to the home page.

The BLOG is your opportunity to ask questions and offer comments. I will make an effort to answer every legitimate question. If I don't know the answer, I will contact the management and get the answer. Alternatively, if you have questions you don't want publicly displayed, you can always email me directly at editor@otcjournal.com. If you submit a comment or question, it will not appear on the site until I have responded.

To use the BLOG, simply go to the home page at www.otcjournal.com - the BLOG scrolls down from the upper right hand corner. The most current journal entries appear on the right hand side of you screen. Check back frequently for updates particularly when stocks are moving to overbought or oversold levels in volatile markets.

Home Page : www.otcjournal.com
Email Questions or Comments To: editor@otcjournal.com

 


If you're going to be an effective an intelligent stock market investor, you must have access to quality, real time data on the markets. This software must include a monitor grid with live quotes showing the bid, offer, last trade, and volume. It has to be dynamic and in real time. You have to see the price changes.

You also need Level II quotes to see what the market makers are doing, Time and Sales where you can see every trade, and live charts with the ability to input any technical data you want to see.

I believe the best software solution on the internet is AlphaTrade- it's reasonably easy to use, and most importantly very inexpensive. A $17 monthly fee is about the lowest out there, and after adding in the unavoidable exchange fees, you're in for about $35 per month.

Alphatrade offers a 2 week free trial for anyone who wants to try the system. However, I know the CEO, and I have arranged a special deal for OTC Journal subscribers. You get a whole month for FREE! No risk. Try it. It's web based, so you can see it out the way you want to see it, and open it on any browser. You don't need to have your own computer.

There's a bit of a learning curve on the software, but it's worth the time to learn how to use it and configure it for your needs. For free, how can you go wrong. Try it. 

Just click on the Alphatrade image, and get started immediately.
 

 

Disclaimer

The OTC Journal Newsletter is an electronic publication committed to providing our readers with useful information on publicly traded companies. The Newsletter contracts with publicly traded companies and receives compensation from them or third parties as payment for publishing information and opinions about the company and the trading market for their securities. Principals of the Newsletter may also purchase or sell securities of the companies in the open market from time to time. The positions, if any, that the Newsletter or its principals presently maintain in the securities of the companies are disclosed here (click here) and should be considered in making an investment decision regarding these companies securities. The Newsletter and its principals reserve the right to acquire additional shares or liquidate some or all of the positions they may hold in the issuer’s securities at any time in the future without further notice. These publications should not be considered to be independent publications concerning the company.

All statements and opinions expressed herein are those of the editors and are subject to change without notice. The Newsletter maintains editorial control over its publications and the companies profiled therein do not have any editorial rights concerning the information published about them. While we believe all sources of information provided by us and contained in our publication to be accurate and reliable, we cannot and do not guarantee the accuracy of information we received from third parties.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.finra.org. We also recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.

The information found in this profile is protected by the copyright laws of the United States and may not be copied, or reproduced in any way without the express written consent of the editors of otcjournal.com.

UNSUBSCRIBE

You can unsubscribe from this list at any time by Clicking Here. If you are having difficulty removing yourself or wish to change your address please go to http://www.otcjournal.com/opt/.